ReP USP - Resultado da busca

Artigo de periodico
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia (2021)
Ribeiro, Renata Scopim ; Machado Neto, João Agostinho ; Eide, Christopher A. ; Silva, Juan Luiz Coelho da ; Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Scheucher, Priscila Santos ; Stevens, Samantha L. Savage ; Campos, Paula de Melo; Saad, Sara T. Olalla ; Palma, Leonardo de Carvalho ; Pontes, Lorena Lobo de Figueiredo ; Simões, Belinda Pinto ; Rego, Eduardo Magalhães ; Tognon, Cristina E. ; Druker, Brian J. ; Traina, Fabiola
Fonte: Investigational New Drugs. Unidades: ICB, FMRP, FM
Assuntos: FARMACOLOGIA, LEUCEMIA MIELOIDE, INSULINA, ANTINEOPLÁSICOS, PROTEÍNAS QUINASES, CÉLULAS SANGUÍNEAS, PROLIFERAÇÃO CELULAR, APOPTOSE, ONCOGENES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Renata Scopim et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, v. 39, n. 3, p. 736-746, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-020-01028-8. Acesso em: 03 nov. 2025.
APA
Ribeiro, R. S., Machado Neto, J. A., Eide, C. A., Silva, J. L. C. da, Fenerich, B. A., Fernandes, J. C., et al. (2021). NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 39( 3), 736-746. doi:10.1007/s10637-020-01028-8
NLM
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Vancouver
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Artigo de periodico
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells (2020)
Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Alves, Ana Paula Nunes Rodrigues; Silva, Juan Luiz Coelho da ; Ribeiro, Renata Scopim; Scheucher, Priscila Santos ; Eide, Christopher A.; Tognon, Cristina E.; Druker, Brian J. ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho ; Traina, Fabiola
Fonte: Signal Transduction and Targeted Therapy. Unidades: FMRP, FM, ICB
Assuntos: FARMACOLOGIA, TRANSDUÇÃO DE SINAL CELULAR, CÉLULAS CULTIVADAS DE TUMOR, ANTINEOPLÁSICOS, PROLIFERAÇÃO CELULAR, ERITROPOIETINA, APOPTOSE, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FENERICH, Bruna Alves et al. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, p. 10 , 2020Tradução . . Disponível em: https://doi.org/10.1038/s41392-019-0102-5. Acesso em: 03 nov. 2025.
APA
Fenerich, B. A., Fernandes, J. C., Alves, A. P. N. R., Silva, J. L. C. da, Ribeiro, R. S., Scheucher, P. S., et al. (2020). NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, 10 . doi:10.1038/s41392-019-0102-5
NLM
Fenerich BA, Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells [Internet]. Signal Transduction and Targeted Therapy. 2020 ; 10 .[citado 2025 nov. 03 ] Available from: https://doi.org/10.1038/s41392-019-0102-5
Vancouver
Fenerich BA, Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells [Internet]. Signal Transduction and Targeted Therapy. 2020 ; 10 .[citado 2025 nov. 03 ] Available from: https://doi.org/10.1038/s41392-019-0102-5
Trabalho de evento-resumo periodico
Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models (2017)
Machado Neto, João Agostinho ; Ribeiro, Renata Scopim; Coelho-Silva, Juan Luiz; Eide, Christopher A.; Fenerich, Bruna Alves; Fernandes, Jaqueline Cristina; Alves, Ana Paula Nunes Rodrigues; Scheucher, Priscila Santos; Tognon, Cristina E.; Figueiredo-Pontes, Lorena Lobo; Druker, Brian J.; Rego, Eduardo Magalhães; Traina, Fabiola
Fonte: Blood. Nome do evento: Annual meeting and Exposition of American Society of Hematology (ASH). Unidades: ICB, FMRP
Assuntos: DOENÇAS HEMATOLÓGICAS, NEOPLASIAS, METFORMINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: http://www.bloodjournal.org/content/130/Suppl_1/4222. Acesso em: 03 nov. 2025. , 2017
APA
Machado Neto, J. A., Ribeiro, R. S., Coelho-Silva, J. L., Eide, C. A., Fenerich, B. A., Fernandes, J. C., et al. (2017). Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Recuperado de http://www.bloodjournal.org/content/130/Suppl_1/4222
NLM
Machado Neto JA, Ribeiro RS, Coelho-Silva JL, Eide CA, Fenerich BA, Fernandes JC, Alves APNR, Scheucher PS, Tognon CE, Figueiredo-Pontes LL, Druker BJ, Rego EM, Traina F. Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models [Internet]. Blood. 2017 ; 130[citado 2025 nov. 03 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/4222
Vancouver
Machado Neto JA, Ribeiro RS, Coelho-Silva JL, Eide CA, Fenerich BA, Fernandes JC, Alves APNR, Scheucher PS, Tognon CE, Figueiredo-Pontes LL, Druker BJ, Rego EM, Traina F. Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models [Internet]. Blood. 2017 ; 130[citado 2025 nov. 03 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/4222
Trabalho de evento-resumo periodico
DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients (2017)
Ribeiro, Renata Scopim; Machado Neto, João Agostinho ; Campos, Paula De Melo; Eide, Christopher A.; Savage, Samantha L.; Lorand-Metze, Irene; Tognon, Cristina E.; Costa, Fernando Ferreira; Druker, Brian J.; Saad, Sara Teresinha Olalla; Traina, Fabiola
Fonte: Blood. Nome do evento: Annual meeting and Exposition of American Society of Hematology (ASH). Unidades: ICB, FMRP
Assuntos: NEOPLASIAS, DOENÇAS HEMATOLÓGICAS, LEUCEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Renata Scopim et al. DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: http://www.bloodjournal.org/content/130/Suppl_1/3969. Acesso em: 03 nov. 2025. , 2017
APA
Ribeiro, R. S., Machado Neto, J. A., Campos, P. D. M., Eide, C. A., Savage, S. L., Lorand-Metze, I., et al. (2017). DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Recuperado de http://www.bloodjournal.org/content/130/Suppl_1/3969
NLM
Ribeiro RS, Machado Neto JA, Campos PDM, Eide CA, Savage SL, Lorand-Metze I, Tognon CE, Costa FF, Druker BJ, Saad STO, Traina F. DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients [Internet]. Blood. 2017 ; 130[citado 2025 nov. 03 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/3969
Vancouver
Ribeiro RS, Machado Neto JA, Campos PDM, Eide CA, Savage SL, Lorand-Metze I, Tognon CE, Costa FF, Druker BJ, Saad STO, Traina F. DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients [Internet]. Blood. 2017 ; 130[citado 2025 nov. 03 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/3969
Artigo de periodico
IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms (2016)
Campos, Paula de Melo; Machado Neto, João Agostinho ; Eide, Christopher A.; Savage, Samantha L.; Scopim-Ribeiro, Renata; Duarte, Adriana da Silva Souza; Favaro, Patrícia; Lorand-Metze, Irene; Costa, Fernando F.; Tognon, Cristina E.; Druker, Brian J.; Saad, Sara T. Olalla; Traina, Fabiola
Fonte: Oncotarget. Unidade: FMRP
Assuntos: REAÇÃO EM CADEIA POR POLIMERASE, APOPTOSE, MUTAÇÃO GENÉTICA, LEUCEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAMPOS, Paula de Melo et al. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget, v. 7, n. 6, p. 6948-6959, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.6851. Acesso em: 03 nov. 2025.
APA
Campos, P. de M., Machado Neto, J. A., Eide, C. A., Savage, S. L., Scopim-Ribeiro, R., Duarte, A. da S. S., et al. (2016). IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget, 7( 6), 6948-6959. doi:10.18632/oncotarget.6851
NLM
Campos P de M, Machado Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, Duarte A da SS, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Saad STO, Traina F. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms [Internet]. Oncotarget. 2016 ; 7( 6): 6948-6959.[citado 2025 nov. 03 ] Available from: https://doi.org/10.18632/oncotarget.6851
Vancouver
Campos P de M, Machado Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, Duarte A da SS, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Saad STO, Traina F. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms [Internet]. Oncotarget. 2016 ; 7( 6): 6948-6959.[citado 2025 nov. 03 ] Available from: https://doi.org/10.18632/oncotarget.6851

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada